Safety and Hemostatic Effectiveness of the Fibrin Pad for Severe Soft-Tissue Bleeding during Abdominal, Retroperitoneal, Pelvic, and Thoracic (Non-cardiac) Surgery: A Randomized, Controlled, Superiority Trial

World Journal of Surgery

Volumn 39, Issue 11, 2015, Pages 2663-2669

  Koea, Jonathan ^a,f   Baldwin, Peter ^b   Shen, Jessica ^c   Patel, B ^c   Batiller, Jonathan ^c   Arnaud, Axel ^c   Hart, James ^c   Hammond, Jeffrey ^c   Fischer, Craig ^d   James Garden, O ^e  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c ETHICON INC   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^f NORTH SHORE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN GLUE;

ABDOMEN; ADULT; ADVERSE EFFECTS; CONTROLLED STUDY; FEMALE; HEMOSTASIS; HUMAN; MALE; MIDDLE AGED; PATIENT SAFETY; PELVIS; RANDOMIZED CONTROLLED TRIAL; RETROPERITONEUM; SURGERY; THORAX SURGERY; TREATMENT OUTCOME; VERY ELDERLY;

ABDOMEN; ADULT; AGED, 80 AND OVER; FEMALE; FIBRIN TISSUE ADHESIVE; HEMOSTASIS, SURGICAL; HUMANS; MALE; MIDDLE AGED; PATIENT SAFETY; PELVIS; RETROPERITONEAL SPACE; THORACIC SURGICAL PROCEDURES; TREATMENT OUTCOME;

EID: 84943197302     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-015-3106-5     Document Type: Article

References (23)

1. Stokes ME, Ye X, Shah M, Mercaldi K et al (2011) Impact of bleeding-related complications and/or blood product transfusions on hospital costs in inpatient surgical patients. BMC Health Serv Res 11:135
2. Marietta M, Facchini L, Pedrazzi P, Busani S, Torelli G (2006) Pathophysiology of bleeding in surgery. Transpl Proc 38(3):812-814
3. Tomizawa Y (2005) Clinical benefits and risk analysis of topical hemostats: a review. J Artif Organs 8(3):137-142
4. Gabay M (2006) Absorbable hemostatic agents. Am J Health Syst Pharm 63(13):1244-1253
5. Voils S (2007) Pharmacologic interventions for the management of critical bleeding. Pharmacotherapy 27(9 Pt 2):69S-84S
6. Ding H, Yuan JQ, Zhou JH, Zheng XY et al (2013) Systematic review and meta-analysis of application of fibrin sealant after liver resection. Curr Med Res Opin 29(4):387-394
7. Chapman WC, Wren SM, Lebovic GS, Malawer M et al (2002) Effective management of bleeding during tumor resection with a collagen-based hemostatic agent. Am Surg 68(9):802-807
8. Fischer CP, Wood CG, Shen J, Batiller J et al (2011) A randomized trial of aprotinin-free fibrin sealant versus absorbable hemostat. Clin Appl Thromb Hemost 17(6):572-577
9. Chan DY, Marshall FF (1999) Partial nephrectomy for centrally located tumors. Urology 54(6):1088-1091 (Discussion 1091-1082)
10. Richter F, Schnorr D, Deger S, Trk I et al (2003) Improvement of hemostasis in open and laparoscopically performed partial nephrectomy using a gelatin matrix-thrombin tissue sealant (FloSeal). Urology 61(1):73-77
11. Baumann P, Schumacher H, Husing J, Luntz S, Knaebel HP (2009) A randomized, controlled, prospective trial to evaluate the haemostatic effect of Lyostypt versus Surgical in arterial bypass anastomosis: "COBBANA" trial. Trials 10:91
12. Hollaus P, Pridun N (1994) The use of Tachocomb in thoracic surgery. J Cardiovasc Surg (Torino) 35(6 Suppl 1):169-170
13. Delgado AV, Kheirabadi BS, Fruchterman TM, Scherer M et al (2008) A novel biologic hemostatic dressing (fibrin patch) reduces blood loss and resuscitation volume and improves survival in hypothermic, coagulopathic Swine with grade V liver injury. J Trauma 64(1):75-80
14. Ward KR, Tiba MH, Holbert WH, Blocher CR et al (2007) Comparison of a new hemostatic agent to current combat hemostatic agents in a Swine model of lethal extremity arterial hemorrhage. J Trauma 63(2):276-283 (Discussion 283-274)
15. Fischer CP, Bochicchio G, Shen J, Patel B et al (2013) A prospective, randomized, controlled trial of the efficacy and safety of fibrin pad as an adjunct to control soft tissue bleeding during abdominal, retroperitoneal, pelvic, and thoracic surgery. J Am Coll Surg 217(3):385-393
16. Koea JB, Batiller J, Patel B, Shen J et al (2013) A phase III, randomized, controlled, superiority trial evaluating the fibrin pad versus standard of care in controlling parenchymal bleeding during elective hepatic surgery. HPB 15(1):61-70
17. Nativ O, Patel B, Shen J, Batiller J et al (2012) Safety and hemostatic efficacy of fibrin pad in partial nephrectomy: results of an open-label phase I and a randomized, standard-of-care-controlled phase I/II study. BMC Nephrol 13:147
18. Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 340:c332
19. Harmonized Tripartite Guideline for Good Clinical Practice (2012). http://www.ich.org. Accessed 27 July 2012
20. US Food and Drug Administration Regulations (2012). http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/. Accessed 27 July 2012
21. Declaration of Helsinki (2012). http://www.wma.net/en/30publications/10policies/b3/. Accessed 26 July 2012
22. European Union Trial Directive (2012). http://ec.europa.eu/health/human-use/clinical-trials/index. Accessed 26 July 2012
23. Guideline on the Clinical Investigation of Plasma Derived Fibrin Sealant/Haemostatic Products (CPMP/BPWG/1089/00). http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003536.pdf